Further evidence that MRI based measurement of midbrain neuromelanin may serve as a proxy measure of brain dopamine activity in psychiatric disorders.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

1. Human Brain Magnetic Resonance Imaging Studies for Psychiatric Disorders: The Current Progress and Future Directions.JMA journal · 2024
   Review
2. Neuromelanin-sensitive MRI as a promising biomarker of catecholamine function.Brain : a journal of neurology · 2024
   Review

Corrections and comments

• Comment on
  Association between neuromelanin-sensitive MRI signal and psychomotor slowing in late-life depression.2021

Authors and funding

1 author at 1 institution in 1 country.

Funding

Abstract

PubMed holds no abstract for this paper.

Indexed as